Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes.
about
Molecular Structure, Membrane Interactions, and Toxicity of the Islet Amyloid Polypeptide in Type 2 Diabetes MellitusAmylin modulates the mesolimbic dopamine system to control energy balance.In silico design of optimal ratio for co-administration of pramlintide and insulin in type 1 diabetes.Characterization of cardiovascular outcomes in a type 2 diabetes glucose supply and insulin demand modelUpper gastrointestinal function and glycemic control in diabetes mellitus.Pramlintide and the treatment of diabetes: a review of the data since its introduction.Amylin activates distributed CNS nuclei to control energy balance.Weight considerations in pharmacotherapy for type 2 diabetesCurrent and future drug targets in weight managementRole of gastrointestinal hormones in feeding behavior and obesity treatment.Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes.Weak Satiety Responsiveness Is a Reliable Trait Associated with Hedonic Risk Factors for Overeating among WomenDiabetes mellitus: new challenges and innovative therapies.Management of Type 2 diabetes: the role of incretin mimetics.Pharmacologic treatment options for obesity: current and potential medications.Glucose homeostasis and the gastrointestinal tract: insights into the treatment of diabetes.Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity.Endogenous VMH amylin signaling is required for full leptin signaling and protection from diet-induced obesity.Mechanisms of current therapies for diabetes mellitus type 2Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk.Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes.New potential adjuncts to treatment of children with type 1 diabetes mellitus.Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy.Control of food intake and energy expenditure by amylin-therapeutic implications.Managing highly insulin-resistant diabetes mellitus: weight loss approaches and medical management.The role of amylin in the control of energy homeostasis.Pharmacologic management of obesity.The interaction of amylin with other hormones in the control of eating.Effects of dietary polyphenols on neuroregulatory factors and pathways that mediate food intake and energy regulation in obesity.Novel therapies for the management of type 2 diabetes mellitus: part 1. pramlintide and bromocriptine-QR.New molecular targets in the pathophysiology of obesity and available treatment options under investigation.Role of Amylin in Type 1 and Type 2 Diabetes.GLP-1 and Amylin in the Treatment of Obesity.Amylin-mediated control of glycemia, energy balance, and cognition.Rationale for treatment options for mealtime glucose control in patients with type 2 diabetes.Amylin.Insulin-associated weight gain in obese type 2 diabetes mellitus patients: What can be done?Through the looking glass: current and future perspectives on the role of hormonal interplay in glucose homeostasis.Efficacy and safety of pramlintide injection adjunct to insulin therapy in patients with type 1 diabetes mellitus: a systematic review and meta-analysis.Optimizing diabetes treatment using an amylin analogue.
P2860
Q26774381-E57D07D3-777B-4C04-84DA-E65D1739968CQ27311258-283CA780-AF82-4FA4-B30E-6BEF13BD5C26Q30410405-70BE7790-D07D-43EF-BA4E-41E18B4CD7E5Q33828259-B23A1150-7597-4C4D-9840-A1D3FEADBF02Q33869207-B1403757-2336-4F91-8D32-EF82DE03AECBQ33896433-254E74FD-EB35-4689-B88B-2177AD9B89E2Q33962500-E40129A0-CF2E-4296-AF96-0F531B74E0F1Q34159414-B3E47E28-AFBC-4828-BFEB-CF9BDD4F4B82Q35089784-A70CDAC6-603A-4687-955F-3E66DA37D768Q35766237-D3FA3C3C-6691-499E-8A2F-7BF161B428AFQ36012965-739AA0D8-E234-426D-B56F-B0663D75C754Q36102087-DC9617E6-D278-441A-AC0D-7C5A670093CBQ36117595-F0B6D1E5-7670-4B41-8867-3E234BE2AC0AQ36613938-D5D0EBFD-5EB8-4DDA-947E-4C036CCA41A5Q36715112-A5538594-6C4D-4291-B8D9-FB35EB1AF1A0Q36816194-F59FF5C7-3AA5-4279-8C5A-60E6011CA528Q36842060-2938E94B-39BF-4BEC-8BAE-A800E5D91D16Q36904734-6501B85E-B86E-45FC-8066-80C35B1E836BQ37180829-FCC2B50A-C37E-4C2A-ACE8-5E027F1594CDQ37193917-12884A84-7CA2-4973-ADF2-28D5700A99C4Q37319183-1DD3160A-8C23-4025-B492-81FFC3356339Q37353820-7E0F093C-CC55-4FDA-BAF3-93FFBCF5895BQ37368085-2619AA5B-775C-488D-81D2-CA6A7328306AQ37442584-D85DE2C4-F03E-402B-9CC4-C23704C91843Q37682560-7532DA93-CAC3-475E-ADE8-C9B9FDE70F75Q37722107-F7B0830A-9626-44EA-AE7A-FE38ED43B0EDQ37947165-CDE7ED97-4774-489C-9839-7E305F32BB2CQ38031993-76ED5665-ED23-481C-903F-BFEA755C5605Q38057717-3312D1AD-3D9D-472D-907A-3C2628F2D47EQ38085727-9BD8FA91-86D0-4AB2-BB67-6444530A30AEQ38397535-5F7FD101-F8F9-4F8F-BFCF-37E4F140EA09Q38596374-D6AD4A58-34AA-4A0F-BCEC-37DA144D971CQ38677851-1EBDC41D-30EF-4E44-A86A-674E4A9A07C7Q38753342-329CDD87-8CF9-4239-82AA-10425190C108Q39101008-17DF27B8-55F4-420D-8E31-D3C3E301BC19Q39293507-D5F34AC1-C804-4926-A732-259DA41DA77CQ39309680-EA4FCDC5-2B07-4BC3-8D4E-2026E3523385Q40215795-D9B6D913-E671-4987-A15A-F1BA28B4584CQ42371659-E4413D7B-4B57-43D4-ACB4-571AE8D0FEA9Q44989550-B58F0074-2D57-428C-AF93-814375D51B1D
P2860
Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Effect of pramlintide on satie ...... subjects with type 2 diabetes.
@en
Effect of pramlintide on satie ...... subjects with type 2 diabetes.
@nl
type
label
Effect of pramlintide on satie ...... subjects with type 2 diabetes.
@en
Effect of pramlintide on satie ...... subjects with type 2 diabetes.
@nl
prefLabel
Effect of pramlintide on satie ...... subjects with type 2 diabetes.
@en
Effect of pramlintide on satie ...... subjects with type 2 diabetes.
@nl
P2093
P1433
P1476
Effect of pramlintide on satie ...... subjects with type 2 diabetes.
@en
P2093
C Feinle-Bisset
M Horowitz
P2888
P304
P356
10.1007/S00125-005-1732-4
P577
2005-04-21T00:00:00Z